Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer Journal Article

  

Authors:	Reichman, B.; Markman, M.; Hakes, T.; Kemeny, N.; Kelsen, D.; Hoskins, W.; Rubin, S.; Lewis, J. L. Jr
Article Title:	Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer
Abstract:	In an effort to maximize both local-regional and systemic drug exposure to tumor in the peritoneal cavity, a phase I study was conducted that examined the simultaneous daily intraperitoneal (IP) and continuous intravenous infusion (CVI) of fluorouracil (5-FU) to 32 patients with refractory cancer. IP 5-FU administered at 1,000 mg/d with concurrent 5-FU by CVI at 1,000 mg/m2/d for four consecutive days was well tolerated. One patient with a primary gastrointestinal (GI) malignancy with minimal volume disease experienced a surgically defined complete remission. In theory, this regimen may demonstrate clinical utility as an adjuvant treatment of certain GI malignancies. Future studies are planned in this clinical setting.
Keywords:	clinical article; fluorouracil; ovary cancer; digestive system cancer; phase 1 clinical trial; peritoneum metastasis; intravenous drug administration; intraperitoneal drug administration; human; aplastic carcinoma
Journal Title:	Journal of Clinical Oncology
Volume:	6
Issue:	1
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	1988-01-01
Start Page:	158
End Page:	162
Language:	English
DOI:	10.1200/jco.1988.6.1.158
PUBMED:	3335888
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023874364&doi=10.1200%2fJCO.1988.6.1.158&partnerID=40&md5=762f24c6a2ff196cc3a96f3a94b64ffd
Notes:	Article -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/170799